Another desperate attempt by Amgen to stay viable!
Amgen has done a wonderful job of inventing and harvesting Epogen and Neupogen.....unfortunately, that is about it. What started as a promising adventure with innovation as its prime principle, has deteriorated into a muddled, confused company where old timers still rule (I tell this from my experience). Like all its acquisitions, they clearly way, way overpaid. Kudos to ONXX Board for extracting a pretty penny from this old big dumb biotech! As for ONXX"s employees, take your profits (from stock options) and run for the hills. Don't join Amgen, I made the mistake and I have regretted it ever since!